Shanghai Hengrui Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Subsidiary

Established: 2001-12-04

Employees: -

Market Cap: -

Website: http://www.shhrp.com

Clinical Trials

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

Phase 3

Not yet recruiting

Conditions: Advanced Urothelial Carcinoma

Interventions: Drug: SHR-A2102 for Injection
Drug: Docetaxel Injection
Drug: Paclitaxel Injection
Drug: Gemcitabine Hydrochloride for Injection
Drug: Pemetrexed Disodium for Injection

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-17

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 402

Registration Number: NCT06738251

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors

Phase 2

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-4602

First Posted Date: 2024-11-26

Last Posted Date: 2024-11-26

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT06704828

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy

Phase 2

Recruiting

Conditions: Advanced Gynecological Malignancy

Interventions: Drug: SHR-A2102 for injection

First Posted Date: 2024-10-23

Last Posted Date: 2024-12-10

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT06654440

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 3

Recruiting

Conditions: Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: SHR-A1904
Drug: Paclitaxel, Docetaxel, Irinotecan

First Posted Date: 2024-10-18

Last Posted Date: 2024-12-12

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 524

Registration Number: NCT06649292

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

Phase 1

Recruiting

Conditions: Advanced Urothelial Carcinoma

Interventions: Drug: SHR-A2102
Drug: Adebrelimab injection
Drug: SHR-8068 injection

First Posted Date: 2024-10-15

Last Posted Date: 2024-11-18

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 90

Registration Number: NCT06639347

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-7787 injection

First Posted Date: 2024-09-20

Last Posted Date: 2024-10-18

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 201

Registration Number: NCT06605222

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: SHR-A2102
Drug: Adebelimab (SHR-1316)
Drug: SHR-8068

First Posted Date: 2024-09-19

Last Posted Date: 2024-11-11

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 124

Registration Number: NCT06589778

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Advanced or Metastatic Non-small Cell Lung Cancer

Interventions: Drug: SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin

First Posted Date: 2024-07-22

Last Posted Date: 2025-01-03

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 248

Registration Number: NCT06512051

Locations: 🇨🇳
Chinese People's Liberation Army General Hospital, Beijing, Beijing, China

Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA

Phase 2

Terminated

Conditions: Postoperative Pain Management in Total Knee Arthroplasty

Interventions: Drug: Ropivacaine Hydrochloride Injection
Drug: HR18034

First Posted Date: 2024-07-19

Last Posted Date: 2024-10-30

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 15

Registration Number: NCT06509958

Locations: 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China

A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-9839 ；SHR-A2009
Drug: SHR-9839 ； pemetrexed ；carboplatin
Drug: SHR-9839 ； Almonertinib
Drug: SHR-9839 ； SHR-A1921

First Posted Date: 2024-06-25

Last Posted Date: 2024-06-25

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 156

Registration Number: NCT06474455

Locations: 🇨🇳
HeNan CANCER HOSPITAL, Zhenzhou, Henan, China
🇨🇳
Zhejiang Cancer Hospital, Zhejiang, HangZhou, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy